TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB41552

Peptide_Name

LSB-37

Activity

Anticancer

Activity_category_statistics

Cancer-related peptides

Database_Source

AntiCP 2.0 CancerPPD 2.0 Peptipedia SATPdb iACP-DRLF

Sequence_Type

standard

Has_Modification No

Description A 38-aa standard natural anticancer peptide sequence curated from AntiCP 2.0, CancerPPD 2.0, Peptipedia, and other sources, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

LPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG-NH2

FASTA

>TPDB41552|Anticancer|length=38
LPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG-NH2

Formula C189H322N54O45

Absent Amino Acids DCQHMSTY

Common Amino Acids K

Mass 4070.97

PI 11.23

Basic Residues 9

Acidic Residues 2

Hydrophobic Residues 18

Net Charge +7

Boman Index 7.91

Hydrophobicity 0.042

Aliphatic Index 115.53

Half Life

Mammalian: 5.5 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 5500

Absorbance 280nm 135.10

Polar Residues 2

number

5

A

2

R

2

N

0

D

0

C

2

E

0

Q

5

G

0

H

4

I

3

L

7

K

0

M

1

F

2

P

0

S

0

T

1

W

0

Y

4

V

Amino Acid Distribution

A: 5 R: 2 N: 2 D: 0 C: 0 E: 2 Q: 0 G: 5 H: 0 I: 4 L: 3 K: 7 M: 0 F: 1 P: 2 S: 0 T: 0 W: 1 Y: 0 V: 4

Length

38

Formula

C189H322N54O45

Mass

4070.97

PI

11.23

Net Charge

+7

Boman Index

7.91

Hydrophobicity

0.042

C_terminal_Modification

Amidation

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Anticancer

Origin

FLAK peptides

Evidence 1 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =50 µg/ml

Detail Source Activity Anticancer

Activity Measurement 50 µg/mL

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =240 µg/ml

Detail Source Activity Anticancer

Activity Measurement 240 µg/mL

Target

Cancer Type Colon Cancer

Cell Line SW-480

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 3 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =170 µg/ml

Detail Source Activity Anticancer

Activity Measurement 170 µg/mL

Target

Cancer Type Skin Cancer

Cell Line BMKC

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 4 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =120 µg/ml

Detail Source Activity Anticancer

Activity Measurement 120 µg/mL

Target

Cancer Type Lung Cancer

Cell Line H-1299

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 5 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =370 µg/ml

Detail Source Activity Anticancer

Activity Measurement 370 µg/mL

Target

Cancer Type Prostate Cancer

Cell Line PC-3

Tissue Affected Prostate

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 6 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =250 µg/ml

Detail Source Activity Anticancer

Activity Measurement 250 µg/mL

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2